Acadia Healthcare (ACHC) & BioTelemetry (BEAT) Financial Survey

Acadia Healthcare (NASDAQ: ACHC) and BioTelemetry (NASDAQ:BEAT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a summary of current recommendations and price targets for Acadia Healthcare and BioTelemetry, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acadia Healthcare 0 5 11 0 2.69
BioTelemetry 1 0 6 0 2.71

Acadia Healthcare currently has a consensus target price of $44.50, indicating a potential upside of 17.17%. BioTelemetry has a consensus target price of $43.67, indicating a potential upside of 26.57%. Given BioTelemetry’s stronger consensus rating and higher possible upside, analysts plainly believe BioTelemetry is more favorable than Acadia Healthcare.

Earnings and Valuation

This table compares Acadia Healthcare and BioTelemetry’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acadia Healthcare $2.84 billion 1.18 $199.83 million $2.30 16.51
BioTelemetry $286.78 million 3.94 -$15.95 million $0.97 35.57

Acadia Healthcare has higher revenue and earnings than BioTelemetry. Acadia Healthcare is trading at a lower price-to-earnings ratio than BioTelemetry, indicating that it is currently the more affordable of the two stocks.


This table compares Acadia Healthcare and BioTelemetry’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acadia Healthcare 6.92% 8.16% 3.15%
BioTelemetry -5.56% 14.54% 8.08%

Risk and Volatility

Acadia Healthcare has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, BioTelemetry has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Institutional & Insider Ownership

87.1% of BioTelemetry shares are held by institutional investors. 11.1% of Acadia Healthcare shares are held by company insiders. Comparatively, 9.6% of BioTelemetry shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


BioTelemetry beats Acadia Healthcare on 8 of the 14 factors compared between the two stocks.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities. The Company is engaged in operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As of December 31, 2016, the U.S. Facilities segment included 208 behavioral healthcare facilities with approximately 8,500 beds in 39 states and Puerto Rico, and the U.K. Facilities segment included 365 behavioral healthcare facilities with approximately 8,600 beds in the United Kingdom. As of December 31, 2016, the Company had operated 573 behavioral healthcare facilities with approximately 17,100 beds in 39 states, the United Kingdom and Puerto Rico.

BioTelemetry Company Profile

BioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania.

Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with's FREE daily email newsletter.

Leave a Reply